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Background: Lateral humeral epicondylitis, or ‘tennis elbow’, is a common condition with a variety of treatment
options. Platelet-rich plasma (PRP) and Autologous Whole Blood (AWB) represent new therapeutic options for
chronic tendinopathies including tennis elbow. The aim of the present study was to compare the long term effects
of PRP versus autologous whole blood local injection in patients with chronic tennis elbow.
Methods: Seventy six patients with chronic lateral humeral epicondylitis with duration of symptoms more than
3 months were included in this study and randomized into 2 groups. Group 1 was treated with a single injection of
2 mL of autologous leukocyte rich PRP (4.8 times of plasma) and group 2 with 2 mL of AWB. Tennis elbow strap,
stretching and strengthening exercises were administered for both groups. Pain and functional improvements were
assessed using visual analogue scale (VAS), Mayo score (modified Mayo Clinic performance index for the elbow)
and pressure pain threshold (PPT) at 0, 4, 8 weeks and 6 and 12 months.
Results: All pain variables including VAS, PPT and Mayo scores improved significantly in both groups at each follow
up intervals compared to baseline. No statistically significant difference was noted between groups regarding pain,
functional scores and treatment success rates in all follow up examinations (P >0/05).
Conclusion: PRP and autologous whole blood injections are both effective methods to treat chronic lateral epicondylitis
and their efficacy persisted during long term follow up. PRP was not superior to AWB in long term follow up.
Keywords: Lateral humeral epicondylitis, Tennis elbow, Platelet rich plasma, Autologous whole bloodBackground
Lateral elbow epicondylar tendinosis or tennis elbow is a
common condition occurring at the common extensor
tendon that originates from the lateral epicondyle in pa-
tients whose activities require strong gripping or repeti-
tive wrist movements [1,2]. It causes pain and functional
impairment in daily activities [1-3].
Histologic findings in chronic cases confirm that
tendinosis is not an acute inflammatory condition but
rather a failure of the normal tendon repair mechanism
associated with angiofibroblastic degeneration [1-3].
Current research has produced several biological hypotheses* Correspondence: lsedighy@yahoo.com
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article, unless otherwise stated.regarding the cause of tendinosis based on histopatho-
logical, biochemical, and clinical findings that show cell
apoptosis, angiofibroblastic features, or abnormal bio-
chemical adaptations, largely suggesting that a failed
healing response underlies the condition [4].
There are a variety of treatment options for this common
condition [5,6]. The treatment is initially conservative.
Numerous methods have been advocated to treat tennis
elbow, including rest, anti inflammatory medications,
bracing, physical therapy, ionotophoresis, extra corporal
shockwave and botulinum toxin. Injections of corticoste-
roids, dry needling and various surgical techniques
can been incorporated in refractory cases [6,7]. However,
these traditional therapies do not alter the tendon’s poor
healing properties secondary to poor vascularization [6].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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options including Platelets Rich Plasma (PRP), autologous
blood, prolotherapy, and extracorporeal shockwave therapy
are aimed at inducing inflammation rather than suppress-
ing it [1,7,8].
Platelet rich plasma is defined as a volume of the
plasma fraction of autologous blood having a platelet
concentration above baseline. Studies have shown that
clinical efficacy can be expected with a minimum in-
crease of 4 times this baseline [9].
Both PRP and autologous blood contain platelets with
strong growth factors that may help in the healing
process of chronic injuries. Known platelet growth fac-
tors stimulate the healing process and lead to partial
modification of the damaged tissue [9-11]. The net re-
sults of PRP therapy in chronic tendinopathies are varied
and hypothesized to include angiogenesis, increase in
growth factor expression and cell proliferation, increase
the recruitment of repair cells also, tensile strength
[9,10]. Due to higher concentration of platelets in PRP
than whole blood, it was suggested in some studies to
have greater effect in the healing and repair process
[12,13]. Various results have been published about appli-
cations of PRP in different fields such as skin and hair,
ENT, orthopaedics etc. [14,15]. PRP use has also been
evaluated in musculoskeletal disorders such as muscular
injuries, achille and lateral epicondyle tendinopathies
and with satisfactory results [8,12].
Some studies have shown that local injection of au-
tologous whole blood has greater therapeutic effect than
steroid injection in treating tennis elbow [10,11], also
there are studies showing the greater efficacy of local au-
tologous PRP than corticosteroids in relieving the symp-
toms of this disorder [9,12]. However, only a few studies
have been conducted to compare the efficacy of these
two treatments. In a comparative study of these 2 treat-
ments conducted by.
Considering the high cost of autologous PRP therapy and
lack of a long term study comparing autologous whole
blood versus PRP injection, the present study was aimed to
evaluate the long term efficacy of autologous whole blood
injection as a less costly treatment versus PRP in patients
suffering from chronic lateral epicondylitis.
Methods
Patients and setting
In this clinical trial, patients with signs and symptoms of
chronic lateral epicondylitis during Sep 2011-Oct 2013
referring to our unit, were evaluated to enter this ran-
domized, single blind study.
Inclusion criteria
Criteria for inclusion in the study were chronic clinically
diagnosed lateral epicondylitis (based on symptoms, siteof tenderness and pain elicited with resisted active ex-
tension of the wrist in pronation and elbow extension);
with duration of symptoms more than 3 months and
pain severity with minimum score of 5 (based on 10
scale VAS (Visual Analogue Score) [16].Exclusion criteria
Patients older than 70 years old, any recent febrile or in-
fectious disease, history of any malignancy (including
hematologic and non hematologic malignancies), carpal
tunnel syndrome, other peripheral nerve injury such as
radial nerve injury, cervical radiculopathy, systemic
illnesses including ischemic heart disease, diabetes,
rheumatoid arthritis, hepatitis, any bony malformations,
bony or articular lesions at elbow (diagnosed by radio-
graphic imaging), history of autoimmune and platelet
disorders, treatment with anticoagulant and anti-platelet
medications 10 days before injection, consistent use of
NSAIDs within 48 hours before procedure, use of sys-
temic steroids during past 3 weeks, haemoglobin mea-
sures of less than 10 g/dl and platelet counts of less than
150,000 per micro liter, history of vasovagal shock, preg-
nancy or breastfeeding.Ethical considerations
From the ethical point of view, we gave written consent to
all patients for inclusion in the study. The process of the
treatment was simplified and explained to the patients,
once the physician assured that the patient completely
understood the study protocol and became aware of his
rights during the study, the written consent form was
signed or fingerprinted by the patient. The institutional re-
view board of Shahid Beheshti University of Medical
Sciences approved the protocol of this study. The process
of treatment had no harm for their health, and they had
authority to stop the process of treatment.
In case of very rare incidence of side effects associated
with PRP or autologous blood injection (persistent pain
and swelling, infection and fibrosis or any neuromuscu-
lar complications at injection site) patients had access
to the project’s physician in order to contact him if they
encountered any of the possible adverse reactions to
injection.Randomization and patients’ enrolment
The block covariate adaptive randomization method is de-
signed to randomize subjects into the treatment groups.
This led to equal sample sizes within each group and bal-
ance of the important covariates. Thus, a new participant
is sequentially assigned to particular treatment groups by
taking into account the specific matched covariates and
previous assignments of participants.
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Group 1 (Autologous PRP group)
The treatment protocol for patients in this group was a
single injection of 2 mL of autologous PRP, deep at the
origin of wrist extensors, into maximal tenderness point
at elbow region under aseptic technique.
PRP preparation
For the process of PRP preparation and injection, partici-
pants were referred to Shahid Modarres hospital laboratory.
The PRP processing was done using the Rooyagen kit
(made by Arya Mabna Tashkhis Corporation, RN: 312569).
For preparing 2 ml of PRP with concentration of 4-6 times
the average normal values, 20 ml of blood was first col-
lected from the patient’s upper limb cubital vein using an
18G needle. Then 2 ml of ACD-A was added to the sample
as an anticoagulant. One ml of the blood sample was sent
for complete blood count. The rest of the sample passed
two stages of centrifuge (first with 1600 rpm for 15 minutes
for separation of erythrocytes and next with 2800 rpm for
7 minutes in order to concentrate platelets). The final prod-
uct was 2 ml of PRP containing leukocytes (leukocyte rich
PRP). The PRP quantification and qualification procedure
was performed using laboratory analyzer Sysmex KX 21
and swirling and if approved, the injection was performed
[17]. We did not use exogenous factor for the process of
platelets activation.
PRP injection
The patient is placed in an appropriate and comfortable
position that allows for sterility and access to the site of
injection.
The skin of the injection site was prepped and draped
and the liquid PRP was injected in a sterile condition
using a 18G needle. The patient received a PRP injection
at maximal point at elbow using a peppering technique
spreading in a clock-like manner to achieve a more expan-
sive zone of delivery.
Group 2 (Autologous whole blood)
Group 2 treatment protocol included a single injection
of 2 mL of autologous peripheral whole blood under the
same technique as the PRP group.
Two ml of lidocaine 1% was injected 8 minutes before
PRP or whole blood injection for patients in both
groups.
No cortisone or nonsteroidal anti-inflammatories were
prescribed during follow-up. For pain relief only, oral
paracetamol and ice therapy were used. Patients of both
groups were requested to refrain from heavy labor activ-
ities for a week. Tennis elbow strap (Oppo trademark)
was administered for all patients and they were instructed
to apply the strap 2 centimetres below the maximal ten-
derness point at elbow.The patients were followed via weekly telephone calls
and instructed how to use elbow splint and perform ex-
ercises. Three days after the injection, each patient was
asked to start a simple program of extensor muscles
stretching and 2 weeks after injection eccentric loading
exercises were prescribed to be performed on an individ-
ual basis twice every day for 5 weeks. The patients were




Pain severity was evaluated before injection and re-
evaluation was done at 4, 8 weeks, 6 and 12 months after
the injection. Visual analogue pain scale (VAS) (range, 0
[no pain] to 10 [agonizing pain]). The validity and reliabil-
ity of self-rating scales like the VAS have previously been
well described [16,18]. Modified Mayo Clinic performance
index score was used to evaluate functional outcome after
the treatment.
Functional outcome measures
Modified Mayo clinic performance index
“Modified Mayo Clinic performance index” for the
elbow was used as a valid and reliable measure to evalu-
ate the functional improvement after therapy [19,20].
The Mayo Clinic performance index for the elbow has 4
parameters: Pain, motion, stability and daily function.
The maximum score is 100 and the minimum index is 0,
the results are interpreted as excellent (> = 90), good
(75-89), fair (60-74) and poor (<60). The pain parameter
carries the highest points (45) [19]. The modified mayo
questionnaire was very specific to changes in elbow
function. The questions were found to be reliable, repro-
ducible and sensitive to change in elbow function [18].
Its construct validity is good for patient-rated variables
and excellent for physician-rated variables. A minimal
clinically important difference of 15 was reported for pa-
tients with rheumatoid arthritis after arthroplasty or
synovectomy [20]. Mayo questionnaire was filled out via
interviewing each patient at each follow up evaluations.
PPT
Pressure Pain Threshold (PPT) was assessed by an alg-
ometer, Commander trademark. The PPT test is precise
and reliable measurement for assessing pain (Cronbach’s
alpha ≥ 0.92). Pressure algometry has been shown to have
good validity when assessed by pain and disability ques-
tionnaires [21]. The algometer is comprised of a gauge at-
tached to a hard rubber tip. Pressure was applied though
the rubber surface area of 1 cm2 at a rate of 2 Kg/Cm2 per
second. The instrument was placed perpendicular to the
skin’s surface. In each algometric assessment, we tested
PPTat two different sites with 2 centimetres distance from
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ness) and the mean of two values was considered as pain
threshold. The method was demonstrated one time at
each site before testing to ensure that the participants
were familiar with the test. The participants were asked to
indicate when the pressure became painful based on this
definition: “When you feel the sensation changes from
pressure to the slightest pain inform us”. Each measure
site was tested three times with 2 minutes between each
test. The scale unit was Kg/cm2.Statistical analysis
SPSS-16 (SPSS Inc Chicago, Illinois, United States of
America) was used for data analysis. According to the
Shapiro-Wilks normality tests, all variables had normal
distribution so parametric tests including T-test, also
Fisher’s exact, GLM: repeated measure and Greenhouse-
Geisser tests were run to compare these variables be-
tween two groups. P-value less than 0.05 was considered
significant. The assessors filling out the questionnaire
and performing PPT, also the statistician were blinded to
the group of the patient. The power of the study was
considered 0.9 for determination of sample size.Figure 1 Consort flow diagram.Results
Seventy six patients were first evaluated for this study,
but finally 61 patients completed the study and their
data was analysed (thirty one patients in PRP and thirty
in autologous group) (CONSORT flow chart Figure 1).
The mean age of patients was 45.3+/-5.9 years old.
Forty seven patients were female (77%) and 14 patients
were male (23%). All patients were right handed. The
mean duration of symptoms in both groups was 14.5 ±
3 months. The patients’ characteristics at study entry
were shown in Table 1. There were no between-group
differences in demographic characteristics and pain in-
tensity at baseline (Table 1).
PRP characteristics
The mean platelets count of all patients at baseline was
250000 ± 53000/μl, which increased to 1227000 ± 250000/μl
(4.8 times concentration) in PRP preparation. Leukocyte
count was 6740 ± 1396/μl in PRP group and 6453 ±
1193/μl in AWB groups.
Outcome measures
All outcomes including VAS and Mayo scores and PPT
were measured before intervention. There were no
Table 1 Demographic characteristics of patients in PRP
and AWB groups
Groups (PRP) (AWB) P-values
Sex
Male 8(26%) 6(20%) P = 0.8
Female 23(74%) 24(80%) Fisher exact test
Side of involvement
Right 19(61) 22(73%) P = 4
Side 12(39%) 18(27%) Fisher exact test
Age 43 ± 6 44 ± 7 P = 0.4
T test
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according to VAS, Mayo and PPT scores. These scores
were measured at 4 and 8 weeks, also 6 and 12 months
after initiating therapy in each group.VAS score
Mean VAS score decreased significantly in both PRP and
AWB groups at each follow up evaluations and at
12 months after therapy compared to baseline. (P < 0.001)
(Table 2, Figure 2).Mayo score
Post intervention (12 month follow up)
Mayo score improved significantly in both PRP and AWB
groups at each follow up evaluations and at 12 months
after therapy compared to baseline (P < 0.001) (Table 3,
Figure 3).PPT score
Post intervention (12 month follow up)
Mean PPT score improved significantly in both groups at
each follow up evaluations and at 12 months after therapy
compared to baseline (P < 0.002) (Table 4, Figure 4).Success rate
Success rate defined as 25% decrease in VAS score com-
pared to baseline was achieved in both treatment groups
in all 3 follow ups (Table 5).Table 2 Mean of VAS score ± sd compared between PRP and
after therapy
Group VAS baseline VAS 4 w
Mean ± sd Mean ± sd
PRP 7.1 ± 1.2 4.17 ± 2.2
AWB 6.8 ± 1.5 4.01 ± 2.3
P-Value 0.4 0.67Between group comparisons
No statistically significant difference was noted between
two groups regarding pain scores (VAS, Mayo and PPT)
and success rate in all follow up examinations including
4,8 weeks and 6 and 12 months after initiating therapy
(Tables 2, 3, 4 and 5, Figures 2, 3 and 4).
Discussion
In the present study, PRP and AWB both lead to signifi-
cant improvement in pain, function and pain pressure
threshold in patients with chronic tennis elbow. How-
ever, this improvement was similar in both treatment
groups which meant the effect of PRP therapy in tennis
elbow management was shown to be almost same as
AWB. Mayo score improvement reached minimal clinic-
ally important difference reported for Mayo score
change following therapy in inflammatory joint disease
in both treatment groups [20]. Also, success rate defined
as 25% decrease in pain scores compared to baseline was
achieved in both groups.
The efficacy of PRP injection for short term and long
term pain relief in lateral epicondylitis was evaluated in
previous studies [9,11,12].
There are many studies in favour of PRP in chronic ten-
dinopathies. In 2006, Mirsha and his colleagues evaluated
treatment of chronic severe elbow tendinosis with PRP.
Eight weeks after the treatment, patients who had received
PRP noted significant improvement in pain scores com-
pared to control group [9]. The effectiveness of PRP com-
pared with corticosteroid injections in patients with
chronic lateral epicondylitis was also determined in a
study by Peerbooms. He found that regarding pain reduc-
tion and functional improvement, corticosteroid was bet-
ter initially and then declined, whereas the PRP group
progressively improved, however this study also lacked a
control group [12].
In 2013 Ahmad Z et al. carried out a systematic review
of the current evidence on the effects of PRP in lateral
epicondylitis on clinical outcomes. In this review, five
randomized controlled trials were included. The largest
randomized controlled trial found that PRP had signifi-
cant benefit compared with corticosteroids with regard
to pain and disabilities of the arm, shoulder and hand
scores at 1 and 2 year time points. The review highlights
the limited but evolving evidence for the use of PRP inAWB groups at baseline, 4, 8 weeks, 6 and 12 months
VAS 8w VAS 6 m VAS 12 m
Mean ± sd Mean ± sd Mean ± sd
3.29 ± 2.05 2.91 ± 2.47 3.29 ± 2.41
3.75 ± 2.05 3.41 ± 2.13 3.94 ± 2.42
0.81 0.318 0.662
Figure 2 Mean (±sd) of VAS score in PRP and Autologous Whole Blood (AWB) groups at baseline, 4, 8 weeks, 6 and 12 months
after therapy.
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by that study to understand the concentration and prepar-
ation that facilitates the best clinical outcome [22]. In an-
other systematic review by Taylor DW seven studies were
evaluated. This review demonstrated favourable outcomes
in tendinopathies in terms of improved pain and functional
scores. The authors concluded that PRP use in tendon and
ligament injuries has several potential advantages, including
faster recovery and possibly, a reduction in recurrence, with
no adverse reactions described [23].
Contrary to the results of our study and the studies
mentioned above, there are some studies showing no sig-
nificant improvement in pain scores after PRP injection.
Such a study was conducted by Shiple BJ conducted to
compare the effectiveness of a single injection of platelet-
rich plasma (PRP), glucocorticoid (GC), or saline in redu-
cing pain in lateral epicondylitis. The pain intensity scale
of the Patient-Rated Tennis Elbow Evaluation (PRTEE)
questionnaire was the main outcome measure (least to
most pain = 0-50 points) [24].Table 3 Mean of Mayo score ± sd compared between PRP and
after therapy
Group Mayo baseline Mayo 4 w
Mean ± sd Mean ± sd
PRP 53.9 ± 16 72.09 ± 16
AWB 48.8 ± 18 70.62 ± 15
P-Value 0.3 0.59Krogh and his colleagues in 2013 randomized 60 sub-
jects into three groups: PRP, corticosteroid or saline injec-
tion. All participants had had tennis elbow for at least
3 months. They found at three months no significant dif-
ference in terms of pain or functional improvement be-
tween the groups. The lack of sufficient number of
platelets in PRP derivatives in above mentioned studies or
different methods of PRP preparation might be one reason
for not getting positive effects from PRP injection [25].
On the other hand, the efficacy of autologous whole
blood injection in treatment of chronic tennis elbow has
been evaluated in a number of studies. In our study au-
tologous whole blood injection lead to significant pain
and functional improvement in chronic tennis elbow.
In a trial in 2010, Kazemi found that at 8 weeks post-
injection that AWB appeared to be more efficacious in
all outcomes (including pain and function) than steroid
injection [P <0.001]. However, there was a high risk of
bias in that study because of inadequate randomization
method [10].AWB groups at baseline, 4, 8 weeks, 6 and 12 months
Mayo 8 w Mayo 6 m Mayo 12 m
Mean ± sd Mean ± sd Mean ± sd
79.51 ± 12 81.20 ± 16 78.18 ± 18
75.04 ± 14 74.91 ± 16 73.16 ± 18
0.597 0.59 0.59
Figure 3 Mean (±sd) of Mayo score in PRP and Autologous Whole Blood (AWB) groups at baseline, 4, 8 weeks, 6 and 12 months
after therapy.
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jection to steroid injection in 60 patients with chronic
tennis elbow. They found that the steroid group demon-
strated better pain relief at 1 and 4 weeks follow-up.
However, at 12 weeks and 6 months, there was signifi-
cantly better pain reduction in the whole blood group
than in the steroid group. Also, there was a greater re-
currence rate in the steroid group compared to the
AWB group (37% vs. 0%) [26].
However, recent reviews of clinical trials revealed lim-
ited evidence supporting the effectiveness of autologous
blood injections for chronic tendinopathies. According
to these reviews, even though refractory chronic tendi-
nopathy might be responsive to AWBs and despite the
proven efficacy of PRP on tissue regeneration in experi-
mental studies, but the data available to date are limited
by quality and size of study, as well as length of follow
up and are currently insufficient to recommend this mo-
dality for routine clinical use [27-30].
In the present study, there was no significant difference
in pain reduction and functional improvement betweenTable 4 Mean of PPT score ± sd compared between PRP and A
after therapy
Group PPT baseline PPT 4 w
Mean ± sd Mean ± sd
PRP 17 ± 5.6 22.4 ± 5.8
AWB 16.9 ± 5.4 20.9 ± 5.3
P-Value 0.9 0.207PRP and AWB injection in chronic tennis elbow in
12 month follow up. The effect of autologous whole blood
in comparison with PRP has been investigated in some
other studies; in a systematic review in 2009 by Rabago,
four injection therapies for lateral epicondylosis: pro-
lotherapy, polidocanol, whole blood and platelet-rich
plasma, whole blood injections were assessed, They re-
ported significant improvement in functional scores and
in maximal grip strength compared with baseline in the
intervention groups. They concluded that according to
existing data for autologous whole blood and PRP injec-
tion, these therapies could be effective in treating tennis
elbow, but as the authors concluded the results of this sys-
tematic review were limited by lack of large definitive clin-
ical trials [31].
Creaney conducted a study of 150 people comparing
whole blood to PRP for the treatment of lateral epicon-
dylitis. The participants had all previously failed to re-
spond to a more ‘conservative’ treatment like stretching
and eccentric exercise. Using the criteria of an improve-
ment of 25 points on the patient-related tennis elbowWB groups at baseline, 4, 8 weeks, 6 and 12 months
PPT 8 w PPT 6 m PPT 12 m
Mean ± sd Mean ± sd Mean ± sd
24 ± 5.5 26.2 ± 6.3 26.9 ± 6.3
22.4 ± 5.9 22.6 ± 6.4 22.5 ± 5.7
0.207 0.207 0.207
Figure 4 Mean (±sd) of PPT score in PRP and Autologous Whole Blood (AWB) groups at baseline, 4, 8 weeks, 6 and 12 months
after therapy.
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both groups and there was no significant difference in
the success rate between either [32]. The results of our
study were in agreement with the results of this study.
In a systematic review in 2012, conducted to determine
the efficacy of autologous blood concentrates in decreas-
ing pain and improving healing and function in patients
with orthopaedic bone and soft-tissue injuries, the authors
evaluated twenty three randomized trials and ten pro-
spective cohort studies and concluded that there is uncer-
tainty about the evidence to support the increasing
clinical use of platelet-rich plasma and autologous blood
concentrates as a treatment modality for orthopaedic bone
and soft-tissue injuries including tennis elbow [33].
In a systematic review and network meta-analysis of
randomized controlled trials by Krogh in 2013, the com-
parative effectiveness and safety of injection therapies in
patients with lateral epicondylitis were assessed. Both
autologous blood and platelet-rich plasma were also sta-
tistically superior to placebo in clinical trials [25].
Generally, there is moderate evidence from two fair
quality (1+) RCTs that platelet-rich plasma is no more
efficacious than autologous blood injections for the
treatment of lateral epicondylitis [32,34].Table 5 Success rate in two groups at 4 follow ups
Groups 4 w 8 w 6 m 12 m
PRP 19 (61%) 23 (75%) 25 (80.6%) 23 (75%)
AWB 19 (63%) 22 (73.3%) 23 (76.6%) 18 (60%)The main factors which may cause controversy in the
studies mentioned above regarding the efficacy of PRP or
whole blood might arise from lack of standardization of
study protocols, platelet-separation and injection tech-
niques whether ultrasound guided or blind, and outcome
measures.
Both PRP and whole blood therapies have been
claimed to promote healing through the action of vari-
ous growth factors on the affected tendon [35]. The
mechanism of action is proposed to be a healing re-
sponse in the damaged tendons triggered by the growth
factors in the blood. These growth factors trigger stem-
cell recruitment, increase local vascularity and produce
an instructional biological microenvironment for local
and migrating cell activities [36].
It is believed that platelet-rich plasma can augment or
stimulate healing by turning on the same biological heal-
ing process that normally occur in the human body after
musculoskeletal injury. However, not only platelet-rich
plasma, but also platelet-poor plasma, stimulates cell
proliferation and total collagen production [37,38]. In-
creased production of endogenous growth factors have
been found in human tendons treated with PRP [3,12,21].
The above mechanism helps explain why PRP alone or
whole blood application can have a lasting effect on the
healing process [23-25].
Conclusion
PRP and autologous whole blood injections are both ef-
fective methods to treat chronic lateral epicondylitis.
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at 12 month follow up in relieving pain and improving
function. It can be concluded from our study that there
might be no need to platelets in higher concentration
than whole blood to get therapeutic effects.
Because PRP and whole blood are autologous and are
prepared at the point of care, they have an excellent safety
profile.
The limitation of our study was the relatively small
number of cases included and absence of a control group
receiving no intervention assigned as the “wait and see”
group. However, long term follow up of patients was a
strong point for the present study.
We encourage more randomized clinical trials on this
topic designed with low risk of bias to investigate the
real efficacy of blood products compared to no treatment,
also the best technique of PRP injection, number and time
of injections and number of platelets. There is also need
for standardisation of PRP preparation methods in all
clinical trials.
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